Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)
Clinical trial NCT05853341 · COMPLETED
Trial details
- NCT number
- NCT05853341
- Sponsor
- Luye Pharma Group Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-02
- Primary completion
- 2023-07-02
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.